Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation - Trial NCT05912205
Access comprehensive clinical trial information for NCT05912205 through Pure Global AI's free database. This Phase 2 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wuhan Union Hospital, China
Timeline & Enrollment
Phase 2
Jul 01, 2023
Jul 01, 2026
Primary Outcome
Bladder-intact event-free survival
Summary
This is a prospective, open, single center clinical study of vidicizumab combined with local
 radiotherapy as bladder conserving therapy in patients with muscle invasive bladder
 urothelium cancer with HER-2 expression (IHC 2+or 3+). A total of 30 subjects were included
 in the study
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05912205
Non-Device Trial